# Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes

> **NCT00690456** · PHASE3 · TERMINATED · sponsor: **Sanofi** · enrollment: 403 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Rimonabant
- **DRUG:** Placebo (for Rimonabant)
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT00690456
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 403 (ACTUAL)
- **Why stopped:** Company decision taken in light of demands by certain national health authorities
- **Last updated:** 2016-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00690456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00690456, "Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00690456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*